Global Market Report for Electronic Nicotine Delivery Systems (ENDS)

Aug.16.2022
Global Market Report for Electronic Nicotine Delivery Systems (ENDS)
The global market for electronic nicotine delivery systems, including e-cigarettes, is predicted to grow rapidly through 2026.

The Business Research Company has released a market research report that predicts the size and trends of the global market for electronic nicotine delivery systems, including e-cigarettes, from 2022 to 2026.


According to a global market report by a business research company, the vaporizer, electronic cigarette, and other electronic nicotine delivery systems (ENDS) market is expected to grow from $19.92 billion in 2021 to $25.03 billion in 2022, with a compound annual growth rate (CAGR) of 25.6%. The market growth is mainly due to companies resuming operations and adapting to a new normal, while recovering from the impact of COVID-19, which earlier resulted in restrictive measures including social distancing, remote work, and the closure of commercial activities, posing operational challenges. The vaporizer, electronic cigarette, and other ENDS market is expected to reach $55.99 billion in 2026, with a CAGR of 22.3%. The awareness of health issues caused by traditional cigarettes among smokers is driving the growth of the electronic cigarette market.


The main trends in the market for vaporizers, electronic cigarettes, and other electronic nicotine delivery systems (ENDS) are as follows: There is an increasing demand for medicinal cannabis vaporizers in the vaporizer market. Cannabis vaporizers have controlled heating technology and can precisely adjust heating temperature through the display screen on the device, allowing users to fully control the density of the aerosol produced. The TBRC's 2022 Global Market Report on Vaporizers, Electronic Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS) includes the following information:


This report categorizes the market based on geographical regions including the Asia Pacific, China, Western Europe, Eastern Europe, North America, the United States, South America, the Middle East, and Africa. It also reflects segmentation by country, including Australia, Brazil, mainland China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom, and the United States, as well as by product type, including atomizers, e-cigarettes, and other electronic nicotine delivery systems. Within these product categories, e-cigarettes can be further divided into disposable, rechargeable, and modular types, while atomizers include e-cigarette atomizers, cannabis atomizers, and medical atomizers. The global market for e-cigarettes and other ENDS can be segmented geographically into North America, South America, the Asia Pacific, Eastern Europe, Western Europe, the Middle East, and Africa. The APAC region holds the largest market share. Leading market players mentioned in the report include Dash Vapes, Hubbly Bubbly, Liquideu, Nice Vapor, Pacific Smoke International, Puff Ecig, Simple Vape Co. London Ltd, Smokio, Vape Escapes, and Vapor Line. The report also highlights current trends, opportunities, strategies, and more. Disclaimer:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness or accuracy of the content. The compilation of this article is only intended for industry exchanges and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the original meaning. Please refer to the original text for accuracy.


In terms of any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions and positions, 2FIRSTS is fully aligned with the Chinese government.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
Philip Morris International’s second-quarter net revenues rose 10.4% to a record $11.19 billion, as heated tobacco and e-vapor expanded across international markets. IQOS remained the main smoke-free growth engine, while VEEV shipments jumped 55.1%. In the United States, however, ZYN shipments increased just 1.8% and consumer offtake was broadly flat to slightly higher. Cigarette volumes also rose, showing that PMI’s transformation is advancing, but growth is becoming increasingly uneven across categories and markets.
PMI
Jul.22
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
ITC Infotech has expanded its multi-year strategic technology partnership with British American Tobacco (BAT), providing technology services across Poland, Romania and India while continuing to support BAT's newly launched Future Capabilities Centre in India and existing technology hubs in Malaysia and Mexico. The companies said the agreement will focus on AI-enabled innovation, technology capability building and greater operational efficiency. The partnership also aligns with BAT's broader Fit2Win transformation programme, under which the group is expanding the use of external technology and business-services partners to simplify its global operating model.
Aug.13
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11